

June 13, 2013

Sylvie Dupont
Director, Board Secretariat
Patented Medicines Prices Review Board
Box L40, Standard Life Centre
333 Laurier Avenue West
Suite 1400
Ottawa, Ontario K1P 1C1



Re: AstraZeneca Canada Inc. Response to PMPRB Notice and Comment on
Regulatory Burden Reduction Initiative

Dear Ms Dupont,

AstraZeneca Canada Inc. is pleased to provide the following comments in response to the PMPRB's Notice and Comment associated with the Regulatory Burden Reduction Initiative.

We would like to express our support for the initiative undertaken by the Board to reduce the regulatory and administrative burden on patentees. It is important to note that the proposed changes will not only reduce costs for patentees, but also have a human impact on those employees having to create and manage the submission of a report in July, allowing them to have greater flexibility in their vacation choices and to allow spending time with their families.

We welcome the proposed amendments to the Guidelines and are aligned to the Rx&D submission on this matter. AstraZeneca is looking forward to discuss further the implementation of these guideline changes and to see them realized in a timely manner.

Sincerely

A handwritten signature in black ink, which appears to read "Mark Findlay". The signature is written in a cursive, flowing style.

Mark Findlay
Vice President, Cornerstone and Market Access